Biochemical Modifications of Pulmonary Surfactant after Bromhexine Derivate Injection

Prévost, Marie-Claude; Soula, G; Douste-Blazy, L

doi:10.1159/000194030

Cited by 23 publications

(12 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Animal studies showed that it enhances both bronchial glandular cell secretions [1 ] and the production of alveolar type II pneumocyte surfactant [2][3][4][5][6][7][8]. It also stimu lates ciliary motility [9,10] and accelerates mucociliary transport [11,12].…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy of Ambroxol in the Treatment of Bronchial Stasis. Clinical Trial in 120 Patients at Two Different Doses

Germouty

Jirou-Najou²

1987

Respiration

View full text Add to dashboard Cite

Mucosolvan is a ‘mucus-modifier’ whose active compound is ambroxol. The aim of our research was to determine its clinical efficacy in the treatment of bronchial stasis by carrying out two successive double-blind studies in two parallel groups of patients and comparing ambroxol with placebo in a treatment lasting 10 days. The first trial involving 60 patients daily treated with 120 mg of ambroxol showed significant differences (p < 0.05) in sputum volume, sputum viscosity, difficulty of expectoration, and severity of cough when compared with the placebo group. The two groups of patients were initially well matched and the drug was well tolerated. In a second trial involving 60 new patients daily treated with 30 mg of ambroxol, the drug showed no clear clinical effects. We conclude that ambroxol is an effective ‘mucus modifier’ and is well tolerated at a dose of 120 mg/day.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy of Ambroxol in the Treatment of Bronchial Stasis. Clinical Trial in 120 Patients at Two Different Doses

Germouty

Jirou-Najou²

1987

Respiration

View full text Add to dashboard Cite

show abstract

“…Increased total phospholipid concen trations were found in lung lavage of rab bits treated with ambroxol [15].…”

Section: Influence O F Ambroxol On the Surfactant Systemmentioning

confidence: 94%

“…[I2]and Prevost et al [15] measured increased specific ac tivity. As specific activity means the ratio of freshly incorporated activity over total concentration of a specific phospholipid (pool size), a decrease should be expected in the case of phospholipase inhibition.…”

Section: Influence O F Ambroxol On the Surfactant Systemmentioning

confidence: 99%

Pharmacodynamic Mechanism and Therapeutic Activity of Ambroxol in Animal Experiments

Disse¹,

H²

1987

Respiration

View full text Add to dashboard Cite

The mucokinetic activity of ambroxol was demonstrated as an increase in mucus or particle transport rate on the frog palate and in guinea pig tracheas. To clarify the mechanism we examined the influence of the drug on the ciliary beat frequency (CBF) of isolated cells from guinea pig tracheas. Ambroxol significantly stimulated the CBF up to 10.8%, salbutamol up to 19.5%. The effect of ambroxol on CBF certainly contributes to, but does not explain the more pronounced increase in transport rate. Thus a stimulation of the mucociliary transport rate by the other major pharmacodynamic mechanisms, secretagogue activity and stimulation of pulmonary surfactant, has to be considered. The therapeutic activity of ambroxol in models of the infant and adult respiratory distress syndrome and of the chronic bronchitic syndrome is reviewed.

show abstract

“…The fact that acebrophylline induced the uptake not only of labeled choline but also of 32 Pphosphate suggests it acts on two levels on surfactant synthesis: the first involves ambroxol's estab- lished action on phosphocholine-cytidyl-transferase [25,26] and the second probably because of theophylline-7 acetic acid's action on choline-kinase [22] (fig. 3).…”

Section: ) Synthesis and Release Of Pulmonary Surfactantmentioning

confidence: 99%

Acebrophylline: an airway mucoregulator and anti-inflammatory agent

Pozzi

2016

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Acebrophylline is an airway mucus regulator with antiinflammatory action. The drug’s approach involves several points of attack in obstructive airway disease. The molecule contains ambroxol, which facilitates various steps in the biosynthesis of pulmonary surfactant, theophylline-7 acetic acid whose carrier function raises blood levels of ambroxol, thus rapidly and intensely stimulating surfactant production. The resulting reduction in the viscosity and adhesivity of the mucus greatly improves ciliary clearance. By deviating phosphatidylcholine towards surfactant synthesis, making it no longer available for the synthesis of inflammatory mediators such as the leukotrienes, acebrophylline also exerts an inflammatory effect. This is confirmed in vivo by the reduction in aspecific bronchial hyperresponsiveness in patients with stable bronchial asthma. On a clinical level, acebrophylline is therapeutically effective in patients with acute or chronic bronchitis, chronic obstructive or asthma-like bronchitis and recurrence of chronic bronchitis; it reduces the frequency of episodes of bronchial obstruction and reduces the need for β2-agonists, and improves indexes of ventilatory function.

show abstract

Biochemical Modifications of Pulmonary Surfactant after Bromhexine Derivate Injection

Cited by 23 publications

References 7 publications

Clinical Efficacy of Ambroxol in the Treatment of Bronchial Stasis. Clinical Trial in 120 Patients at Two Different Doses

Clinical Efficacy of Ambroxol in the Treatment of Bronchial Stasis. Clinical Trial in 120 Patients at Two Different Doses

Pharmacodynamic Mechanism and Therapeutic Activity of Ambroxol in Animal Experiments

Acebrophylline: an airway mucoregulator and anti-inflammatory agent

Contact Info

Product

Resources

About